Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Bath Savings Trust Co

Bath Savings Trust Co grew its position in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,347 shares of the medical research company’s stock after purchasing an additional 222 shares during the period. Bath Savings Trust Co’s holdings in Thermo Fisher Scientific were worth $2,838,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Phoenix Holdings Ltd. lifted its position in Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after acquiring an additional 1,654 shares in the last quarter. DMC Group LLC lifted its position in Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after acquiring an additional 84 shares in the last quarter. Montchanin Asset Management LLC lifted its position in Thermo Fisher Scientific by 1.1% during the 2nd quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company’s stock worth $2,374,000 after acquiring an additional 50 shares in the last quarter. Check Capital Management Inc. CA acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $219,000. Finally, Tower Bridge Advisors lifted its position in Thermo Fisher Scientific by 0.5% during the 3rd quarter. Tower Bridge Advisors now owns 33,046 shares of the medical research company’s stock worth $16,727,000 after acquiring an additional 155 shares in the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have issued reports on TMO. Citigroup lifted their price objective on Thermo Fisher Scientific from $530.00 to $575.00 and gave the stock a “buy” rating in a report on Monday, December 11th. Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective on the stock. HSBC began coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They set a “buy” rating and a $610.00 price objective on the stock. Finally, TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $596.00.

View Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $584.15 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The business’s fifty day moving average price is $559.33 and its two-hundred day moving average price is $518.31. The firm has a market capitalization of $222.74 billion, a PE ratio of 37.81, a P/E/G ratio of 2.49 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the company earned $5.40 earnings per share. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.